Page last updated: 2024-12-05

equilenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Equilenin: An estrogenic steroid produced by HORSES. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the URINE of pregnant mares. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

equilenin : A 3-hydroxy steroid that is estrone which carries two double bonds at positions 6 and 8. It is found in the urine of pregnant mare's and extensively used for estrogen replacement therapy in postmenopausal women. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID444865
CHEMBL ID225546
CHEBI ID34739
SCHEMBL ID120922
MeSH IDM0007616

Synonyms (41)

Synonym
LMST02010007
3-hydroxy-estra-1,3,5(10),6,8-pentaen-17-one
d-equilenin
brn 2335367
nsc 9901
ccris 9075
equilenina [spanish]
einecs 208-230-5
3-hydroxyoestra-1,3,5(10),6,8-pentaen-17-one
equilenin
517-09-9
equilenine
equ ,
3-hydroxyestra-1,3,5(10),6,8-pentaen-17-one
1OGX
DB03515
1W6Y
1OGZ
(13s,14s)-3-hydroxy-13-methyl-12,14,15,16-tetrahydro-11h-cyclopenta[a]phenanthren-17-one
CHEMBL225546
4-08-00-01420 (beilstein handbook reference)
w8ftj17c4j ,
unii-w8ftj17c4j
bdbm50423545
SCHEMBL120922
equilenin [mi]
3-hydroxyestra-1,3,5,7,9-pentaen-17-one
DTXSID2052156
d-3-hydroxy-1,3,5(10),6,8-estrapentaen-17-one
(3as,11as)-7-hydroxy-11a-methyl-2,3,3a,10,11,11a-hexahydro-1h-cyclopenta[a]phenanthren-1-one
(+)-equilenin
CHEBI:34739
6,8-didehydroestrone
AKOS030240677
equilenin 100 microg/ml in acetonitrile
3-hydroxyestra-1(10),2,4,6,8-pentaen-17-one
Q5384461
3-hydroxy-13-methyl-11,12,13,14,15,16-hexahydrocyclopenta[a]phenanthren-17-one
(13s)-3-hydroxy-13-methyl-12,13,15,16-tetrahydro-11h-cyclopenta[a]phenanthren-17(14h)-one
e 400
(3as,11as)-7-hydroxy-11a-methyl-1h,2h,3h,3ah,10h,11h,11ah-cyclopenta[a]phenanthren-1-one

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The mean half-life of the slower component of equilin sulfate is 190 +/- 23 min, and the mean MCR is 176 +/- 44 liters/day ."( Pharmacokinetics of equilin and equilin sulfate in normal postmenopausal women and men.
Benoit, H; Bhavnani, BR; Wong, T; Woolever, CA, 1983
)
0.27

Bioavailability

ExcerptReferenceRelevance
" Its applicability to the study of estrogen bioavailability and bioequivalence is suggested."( Reversed-phase liquid chromatographic method for estrogen determination in equine biological samples.
Lima, SB; Ribeiro Neto, LM; Verreschi, IT, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
" An immunoassay with 4OHEN-1 revealed a linear dose-response between known amounts of 4-OHEN-DNA adducts and the antibody binding to those adducts, with a detection limit of approximately five adducts/10(8) bases in 1 microg DNA sample."( Quantitative detection of 4-hydroxyequilenin-DNA adducts in mammalian cells using an immunoassay with a novel monoclonal antibody.
Itoh, S; Iwamoto, T; Mori, T; Nishiwaki, T; Okahashi, Y; Shibutani, S; Sugiura, S; Suzuki, N; Ueno, S, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
mammalian metaboliteAny animal metabolite produced during a metabolic reaction in mammals.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
3-hydroxy steroidAny hydroxy steroid carrying a hydroxy group at position 3.
17-oxo steroidAny oxo steroid carrying the oxo group at position 17.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Steroid Delta-isomeraseComamonas testosteroniKd1.40001.40001.40001.4000AID977611
Sex hormone-binding globulinHomo sapiens (human)Kd0.00240.00020.34964.7863AID318680
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID90796Compound was evaluated for percentage inhibition of Interleukin (IL1-beta) release in human monocytes at a concentration of 1000 nM.1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
Novel cytokine release inhibitors. Part II: Steroids.
AID468985Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID282836Cytotoxicity against human HL60 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID468984Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID1811Experimentally measured binding affinity data derived from PDB2003The Biochemical journal, Oct-15, Volume: 375, Issue:Pt 2
The conserved cis-Pro39 residue plays a crucial role in the proper positioning of the catalytic base Asp38 in ketosteroid isomerase from Comamonas testosteroni.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2003The Biochemical journal, Oct-15, Volume: 375, Issue:Pt 2
The conserved cis-Pro39 residue plays a crucial role in the proper positioning of the catalytic base Asp38 in ketosteroid isomerase from Comamonas testosteroni.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (130)

TimeframeStudies, This Drug (%)All Drugs %
pre-199041 (31.54)18.7374
1990's23 (17.69)18.2507
2000's53 (40.77)29.6817
2010's12 (9.23)24.3611
2020's1 (0.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other132 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]